Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-γ agonists

被引：20

作者：

Shen, WT ^{[1
]}

Chung, WY ^{[1
]}

机构：

[1] Univ Calif San Francisco, Mt Zion Med Ctr, Dept Surg, San Francisco, CA 94143 USA

来源：

THYROID | 2005年 / 15卷 / 06期

关键词：

D O I：

10.1089/thy.2005.15.594

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Among the most promising new antineoplastic therapies for poorly differentiated or undifferentiated thyroid cancer are the histone deacetylase inhibitors and the peroxisome proliferator-activated receptor (PPAR)-gamma agonists. These two classes of drugs have been shown to inhibit growth and induce apoptosis and redifferentiation in a variety of hematologic and solid cancer cell lines and animal models. In this article we review the molecular mechanisms, in vitro and in vivo studies, and clinical applications of the histone deacetylase inhibitors and PPAR-gamma agonists in the treatment of thyroid cancer.

引用

页码：594 / 599

页数：6

共 50 条

[1] Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas [J].

Aldred, MA ;

Morrison, C ;

Gimm, O ;

Hoang-Vu, C ;

Krause, U ;

Dralle, H ;

Jhiang, S ;

Eng, C .

ONCOGENE, 2003, 22 (22) :3412-3416

[2] Beyond radioiodine: A review of potential new therapeutic approaches for thyroid cancer [J].

Braga-Basaria, M ;

Ringel, MD .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :1947-1960

[3] Detection of the PAX8-PPARγ fusion oncogene in both follicular thyroid carcinomas and adenomas [J].

Cheung, L ;

Messina, M ;

Gill, A ;

Clarkson, A ;

Learoyd, D ;

Delbridge, L ;

Wentworth, J ;

Philips, J ;

Clifton-Bligh, R ;

Robinson, BG .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01) :354-357

[4] Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells [J].

Donadelli, M ;

Costanzo, C ;

Faggioli, L ;

Scupoli, MT ;

Moore, PS ;

Bassi, C ;

Scarpa, A ;

Palmieri, M .

MOLECULAR CARCINOGENESIS, 2003, 38 (02) :59-69

[5]

Dressel U, 2000, ANTICANCER RES, V20, P1017

[6] Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors [J].

Dwight, T ;

Thoppe, SR ;

Foukakis, T ;

Lui, WO ;

Wallin, G ;

Höög, A ;

Frisk, T ;

Larsson, C ;

Zedenius, J .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4440-4445

[7] Trichostatin A modulates expression of p21waf1/cip1, Bcl-xL, ID1, ID2, ID3, CRABP, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells [J].

Eickhoff, B ;

Rüller, S ;

Laue, T ;

Köhler, G ;

Stahl, C ;

Schlaak, M ;

van der Bosch, J .

BIOLOGICAL CHEMISTRY, 2000, 381 (02) :107-112

[8] Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells [J].

Fortunati, N ;

Catalano, MG ;

Arena, K ;

Brignardello, E ;

Piovesan, A ;

Boccuzzi, G .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :1006-1009

[9]

Furumai R, 2002, CANCER RES, V62, P4916

[10] Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin [J].

Furuya, F ;

Shimura, H ;

Suzuki, H ;

Taki, K ;

Ohta, K ;

Haraguchi, K ;

Onaya, T ;

Endo, T ;

Kobayashi, T .

ENDOCRINOLOGY, 2004, 145 (06) :2865-2875

← 1 2 3 4 5 →